

**SIGNATURE PRIORITY**

## James P. Allison Institute

### A new era for immunotherapy

To bring the benefits of immunotherapy to all patients, MD Anderson Cancer Center launched the **James P. Allison Institute™** — a research and innovation powerhouse that fuels scientific progress, nurtures next-generation trailblazers, develops new therapies and saves lives. The **Allison Institute™** expands on the legacy of pioneering immunologist and Nobel laureate James Allison, Ph.D. His groundbreaking studies of T cell biology — and development of the first immune checkpoint inhibitor — were the first steps that launched the field of immunotherapy.

Today, immunotherapy is a standard treatment option alongside surgery, radiation, chemotherapy and targeted cancer therapy. MD Anderson and the Allison Institute aim to lead the world in immunotherapy research, accelerating discoveries into new and synergetic therapies that enable cures.

The Allison Institute's foundational commitment to exceptional discovery science equips us to reach a profound understanding of immunological mechanisms. From those fundamental discoveries, the Allison Institute enables rapid translation of breakthroughs into new therapies and combinations to be evaluated in impactful clinical trials. Working across disciplines — cancer biology, immunology, genetics, bioinformatics, data science and more — the Allison Institute approaches immunotherapy in pioneering ways, revealing promising paths of discovery and pointing the compass toward a healthier future.

## MISSION

Eliminate cancer in Texas, the nation and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public

## 5 THINGS TO KNOW ABOUT MD ANDERSON

- MD Anderson Cancer Center is ranked No. 1 in the nation for cancer care in U.S. News & World Report's "Best Hospitals" survey and has been named one of the nation's top two hospitals for cancer care since the survey began in 1990
- Saw 187,000 patients, completed 1.7 million outpatient visits and delivered \$346 million in uncompensated care in the past fiscal year
- Home to the world's largest cancer clinical trials program
- Invested \$1.3 billion in research in the past fiscal year
- Received 188 patents and tested 27 drugs that received Food and Drug Administration (FDA) approval in the past fiscal year

To learn more, visit [MDAnderson.org/QuickFacts](https://MDAnderson.org/QuickFacts)

